Skip to main content

Postmenopausal bleeding

Gynaecology

Clinic, referred promptly

The first question

Is this endometrial cancer, until proven otherwise?

  1. 01

    Confirm

    Bleeding a year or more after the last period, or unscheduled bleeding on hormone therapy; separate from urinary or rectal bleeding.

  2. 02

    Examine

    Vulva, vagina, cervix on speculum; screening if due; bimanual.

  3. 03

    Transvaginal ultrasound

    Endometrial thickness: 4 mm or less makes cancer unlikely; more, or persistent bleeding, means sampling.

  4. 04

    Sample

    Office endometrial biopsy; hysteroscopy with biopsy if inadequate, if a polyp is seen, or if bleeding persists.

Where it is

Each opens the structure on the 3D pelvis.

History that discriminates

  • Amount and pattern, time since menopause
  • Hormone therapy and its regimen, tamoxifen
  • Obesity, diabetes, hypertension, nulliparity, PCOS history
  • Family history of endometrial, colorectal or ovarian cancer (Lynch)
  • Anticoagulants
  • Vaginal dryness, dyspareunia

Examination that discriminates

  • Vulva and vagina: atrophy, lesions
  • Speculum: cervix, polyps, contact bleeding, source
  • Bimanual: uterine size, adnexal masses

Investigations

  • Transvaginal ultrasound
  • Endometrial biopsy
  • Hysteroscopy
  • Cervical screening if due
  • CBC

The differential

DiagnosisFavoursAgainstUrgency
Endometrial cancer or hyperplasiaThickened endometrium, risk factors, persistent bleedingThin endometrium and a single episodeurgent
Atrophic endometrium or vaginitisThin endometrium, atrophic vagina, light spottingThickened endometriumroutine
Endometrial or cervical polypPolyp on scan or speculumNone seenroutine
Hormone therapy bleedingExpected withdrawal on a cyclical regimen; early months of a continuous oneBleeding after the first 6 months of continuous therapy, or heavyroutine
Cervical cancerVisible lesion, postcoital bleeding, no screening historyNormal cervix and screeningurgent
Vulvar or vaginal lesionVisible lesionNormal examinationurgent

Pitfalls this pathway refuses

  • Attributing bleeding to atrophy without a scan
  • Stopping after a thin endometrium when bleeding recurs
  • Not examining the vulva and cervix

Frameworks

  • FIGO: The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes (PALM-COEIN), 2018 revisions (2018).
  • SOGC: Guideline: menopause and its management (2021).